Medicine guide
Zinbryta
·
- Prescription status not stated
- Cancer treatments and immune-system medicines
- Active substance
- Daclizumab
- Made by
- Biogen Idec Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis (RMS).
From the official label · 2026-09-30 · European Medicines Agency
Details
| Made by | Biogen Idec Ltd |
|---|---|
| Active substance | Daclizumab |
| Used in | Cancer treatments and immune-system medicines |
| Classification | L04AC01 · Cancer treatments and immune-system medicines |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2016-07-01 |
| Last updated by the regulator | 2018-06-28 |
| EMA product number | EMEA/H/C/003862 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.